IPQ Inside the global regulatory dialogue

Significance of 483 Observations Depends on Product Impact, FDA Compliance Officials Explain

Oct 31st, 2011

Please Log in to print the full article

FDA compliance officials are stressing that their judgment of the significance of an investigator's 483 observation is case-specific, reflecting its implications for the quality of product(s) and the firm’s transparency with the agency about that...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications